ASO VISUAL ABSTRACT

ASO Video Abstract: Microsatellite Instability and the Effectiveness of Adjuvant Treatment in pT1N1 Gastric Cancer—A Multi-cohort Study

Namkee Oh, MD¹, Hyunki Kim, MD, PhD², Kyoung-Mee Kim, MD, PhD³, Jae-Ho Cheong, MD, PhD⁴, Jeeyun Lee, MD, PhD⁵, Sung Hoon Noh, MD, PhD⁴, Tae Sung Sohn, MD, PhD¹, Yoon Young Choi, MD, PhD^{4,6}, and Ji Yeong An, MD, PhD¹

¹Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;

²Department of Pathology, Yonsei University College of Medicine, Seoul, Korea; ³Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;

⁴Department of Surgery, Yonsei University College of Medicine, Seoul, Korea; ⁵Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;

⁶Department of Surgery, CHA Ilisan Hospital, CHA University School of Medicine, Ilisan, Korea

Our study aimed to investigate the usefulness of microsatellite status in predicting prognosis and response to adjuvant treatment in pT1N1 gastric cancer (<https://doi.org/10.1245/s10434-021-10084-0>). MSI status may not be

a prognostic factor for tumor recurrence or a predictor of response to adjuvant treatment in pT1N1 gastric cancer patients.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1245/s10434-021-10127-6>.

© Society of Surgical Oncology 2021

Published Online: 5 September 2021

Y. Y. Choi, MD, PhD
e-mail: biosurgeon98@chamc.co.kr

J. Y. An, MD, PhD
e-mail: jar319.an@samsung.com